Comparison 11. Hyalgan versus methylprednisolone acetate.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Spontaneous pain intensity (0‐100 mm VAS)	3		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
1.1 1 to 4 weeks post‐injection	3	170	Mean Difference (IV, Fixed, 95% CI)	‐4.90 [‐9.91, 0.10]
1.2 5 to 13 weeks post‐injection	3	170	Mean Difference (IV, Fixed, 95% CI)	‐7.73 [‐12.81, ‐2.64]
1.3 45 to 52 weeks post‐injection	1	32	Mean Difference (IV, Fixed, 95% CI)	2.5 [‐14.98, 19.98]
2 Number of joints with moderate or severe walking pain	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
2.1 1 to 4 weeks post‐injection	1	40	Risk Ratio (M‐H, Fixed, 95% CI)	1.22 [0.65, 2.29]
2.2 5 to 13 weeks post‐injection	1	40	Risk Ratio (M‐H, Fixed, 95% CI)	0.8 [0.40, 1.60]
2.3 45 to 52 weeks post‐injection	1	32	Risk Ratio (M‐H, Fixed, 95% CI)	1.04 [0.67, 1.60]
3 Number of patients with moderate or severe pain under load	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
3.1 1 to 4 weeks post‐injection	2	130	Risk Ratio (M‐H, Fixed, 95% CI)	0.95 [0.71, 1.27]
3.2 5 to 13 weeks post‐injection	2	129	Risk Ratio (M‐H, Fixed, 95% CI)	0.62 [0.45, 0.85]
4 Number of joints with moderate or severe pain under load	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
4.1 1 to 4 weeks post‐injection	1	40	Risk Ratio (M‐H, Fixed, 95% CI)	1.0 [0.47, 2.14]
4.2 5 to 13 weeks post‐injection	1	40	Risk Ratio (M‐H, Fixed, 95% CI)	0.86 [0.35, 2.10]
4.3 45 to 52 weeks post‐injection	1	32	Risk Ratio (M‐H, Fixed, 95% CI)	0.82 [0.46, 1.49]
5 Number of patients with at least moderate or greater night pain	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
5.1 1 to 4 weeks post‐injection	2	130	Risk Ratio (M‐H, Fixed, 95% CI)	1.2 [0.38, 3.80]
5.2 5 to 13 weeks post‐injection	2	129	Risk Ratio (M‐H, Fixed, 95% CI)	0.14 [0.02, 1.13]
6 Number of patients with moderate or greater rest pain	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
6.1 1 to 4 weeks post‐injection	2	130	Risk Ratio (M‐H, Fixed, 95% CI)	0.68 [0.38, 1.24]
6.2 5 to 13 weeks post‐injection	2	129	Risk Ratio (M‐H, Fixed, 95% CI)	0.39 [0.19, 0.78]
7 Function: range of motion (flexion in degrees)	2		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
7.1 1 to 4 weeks post‐injection	2	130	Mean Difference (IV, Fixed, 95% CI)	5.93 [0.71, 11.14]
7.2 5 to 13 weeks post‐injection	2	130	Mean Difference (IV, Fixed, 95% CI)	5.41 [0.54, 10.28]
7.3 45 to 52 weeks post‐injection	1	32	Mean Difference (IV, Fixed, 95% CI)	1.5 [‐12.92, 15.92]
8 Patient global (number of patients very good or good, excellent or /good)	3		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
8.1 1 to 4 weeks post‐injection	3	213	Risk Ratio (M‐H, Fixed, 95% CI)	0.94 [0.75, 1.18]
8.2 5 to 13 weeks post‐injection	2	130	Risk Ratio (M‐H, Fixed, 95% CI)	1.86 [1.26, 2.75]
8.3 14 to 26 weeks post‐injection	1	70	Risk Ratio (M‐H, Fixed, 95% CI)	1.05 [0.81, 1.36]
9 Safety: total withdrawals overall	4		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
9.1 1 to 4 weeks post‐injection	1	99	Risk Ratio (M‐H, Fixed, 95% CI)	0.54 [0.21, 1.38]
9.2 5 to 13 weeks post‐injection	2	130	Risk Ratio (M‐H, Fixed, 95% CI)	3.0 [0.13, 71.74]
9.3 14 to 26 weeks post‐injection	1	99	Risk Ratio (M‐H, Fixed, 95% CI)	1.81 [0.67, 4.91]
9.4 45 to 52 weeks post‐injection	1	40	Risk Ratio (M‐H, Fixed, 95% CI)	1.67 [0.46, 6.06]
10 Safety: number of patients withdrawn due to lack of efficacy	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
10.1 5 to 13 weeks post‐injection	1	90	Risk Ratio (M‐H, Fixed, 95% CI)	3.0 [0.13, 71.74]
11 Safety: number of patients withdrawn due to adverse events	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
11.1 After first injection	1	99	Risk Ratio (M‐H, Fixed, 95% CI)	0.30 [0.01, 7.24]
12 Safety: number of patients with local or systemic reactions	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
12.1 5 to 13 weeks post‐injection	2	130	Risk Ratio (M‐H, Fixed, 95% CI)	3.0 [0.13, 71.74]
13 Safety: number of joints with local reactions but continued in trial	1		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
13.1 1 to 4 weeks post‐injection	1	40	Risk Ratio (M‐H, Fixed, 95% CI)	1.33 [0.34, 5.21]